Table 1.
Clinical and Pathologic Characteristics
| Variable | Neoadjuvant Group | Operable Group | ||
|---|---|---|---|---|
| n | % | n | % | |
| Number of Patients | 44 | 41 | ||
| Age (y) | ||||
| Mean | 50 6 | 51.6 | ||
| Median | 48.5 | 49 | ||
| Range | 30–76 | 34–83 | ||
| Histologic Grade | ||||
| I | 0 | 0 | 7 | 17.1 |
| II | 13 | 29.5 | 13 | 31.7 |
| III | 31 | 70.5 | 21 | 51.2 |
| ER Status | ||||
| Positive | 20 | 45.5 | 22 | 45.5 |
| Negative | 24 | 54.5 | 19 | 54.5 |
| HER2/neu Status | ||||
| Positive | 8 | 18.2 | 11 | 26.8 |
| Negative | 36 | 81.8 | 30 | 73.2 |
| Pathologic Stage at Surgery | ||||
| T0 | 5 | 11.4 | 0 | 0 |
| T1 | 20 | 45.5 | 20 | 48.8 |
| T2 | 16 | 36.4 | 14 | 34.1 |
| T3 | 2 | 4.5 | 6 | 14.6 |
| T4 | 1 | 2.3 | 1 | 2.4 |
| Nx | 1 | 2.3 | 3 | 7.3 |
| N0 | 15 | 34.1 | 19 | 46.3 |
| N1 | 15 | 34.1 | 12 | 29.3 |
| N2 | 13 | 29.5 | 7 | 17.1 |
| Chemotherapy Used | ||||
| Taxane-containing | 33 | 75 | – | – |
| Other chemotherapy | 11 | 25 | – | – |
Abbreviations: ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2.